Transcriptional Profiling of Human Monocytes Identifies the Inhibitory Receptor CD300a as Regulator of Transendothelial Migration

Sharang Ghavampour, Carsten Lange, Cristina Bottino, Volker Gerke

1 Center for Molecular Biology of Inflammation, Institute of Medical Biochemistry, Muenster, Germany, 2 Dipartimento di Medicina Sperimentale, Sezione di Patologia Generale, Laboratorio di Immunologia Clinica e Sperimentale, Instituto Giannina Gaslini, Genova, Italy

**Abstract**

Local inflammatory responses are characterized by the recruitment of circulating leukocytes from the blood to sites of inflammation, a process requiring the directed migration of leukocytes across the vessel wall and hence a penetration of the endothelial lining. To identify underlying signalling events and novel factors involved in these processes we screened for genes differentially expressed in human monocytes following their adhesion to and passage through an endothelial monolayer. Functional annotation clustering of the genes identified revealed an overrepresentation of those associated with inflammation/immune response, in particular early monocyte to macrophage differentiation. Among the gene products so far not implicated in monocyte transendothelial migration was the inhibitory immune receptor CD300a. CD300a mRNA and protein levels were upregulated following transmigration and engagement of the receptor by anti-CD300a antibodies markedly reduced monocyte transendothelial migration. In contrast, siRNA mediated downregulation of CD300a in human monocytes increased their rate of migration. CD300a colocalized and cosedimented with actin filaments and, when activated, caused F-actin cytoskeleton alterations. Thus, monocyte transendothelial migration is accompanied by an elevation of CD300a which serves an inhibitory function possibly required for termination of the actual transmigration.

**Introduction**

The inflammatory response of vascularized tissue to perturbations such as injury and infection is characterized by the recruitment of circulating leukocytes to the actual site of perturbation. In order to reach these sites, leukocytes have to penetrate the vessel wall in a directional manner. This process is governed by a cascade of interactions between leukocyte and endothelial cell surface molecules. Following inflammatory stimulation leukocytes engage in initial, primarily selectin-mediated interactions with the activated endothelium that typically lead to tight adhesive contacts mediated by integrins, whose activity is increased upon stimulation of leukocyte chemokine receptors. Finally leukocytes transverse the endothelial blood vessel lining through a paracellular, in some cases also transcellular, route that requires the activity of several endothelial adhesion molecules such as PECAM, CD99, VE-cadherin and JAM family proteins (for reviews see [1–5]).

Different signaling pathways are triggered in migrating leukocytes upon interaction with endothelial cells (for reviews see [2,4,6,7]). Activation of these signaling cascades is associated with leukocyte cell polarization and directional movement, which collectively support migration on and finally through the endothelial cell layer. In addition, the engagements of integrins and other adhesion receptors have been linked to the regulation of leukocyte gene expression and mRNA stability [8,9]. The genes affected range from transcription factors, metabolic enzymes and kinases to cell adhesion molecules. Some of these gene expression changes contribute to leukocyte differentiation [10] and, consequently, leukocyte functions in the inflamed tissue (for an overview see [11]). Gene expression changes have also been analyzed specifically in monocyte subpopulations following activation of inflammatory migration. Such expression profiles revealed an upregulation of certain chemoattractants, proteases possibly required for migration and pattern recognition receptors [12]. Furthermore, following adhesion to naive endothelium primary monocytes have been shown to undergo significant gene expression changes towards a more differentiated phenotype [13].

To extend these observations we sought to obtain a comprehensive overview of monocyte gene expression regulation during the process of transendothelial migration. This was achieved by recording global gene expression profiles of transmigrated versus stationary control monocytes and led to the identification of 81 up- and 75 downregulated mRNAs showing an expression change of at least 1.8 fold. CD300a was among the upregulated genes. It belongs to the group of inhibitory immune receptors that can act as negative regulators countering excessive inflammation. Inhibitory receptors have been first characterized on cytotoxic T
cells and natural killer (NK) cells because of their ability to terminate the cytotoxic activity of these cells [14,15]. CD300a is a 60-KD type I transmembrane glycoprotein containing a single extracellular Ig domain and three classical ITIM motifs in its cytoplasmic tail. It is expressed in NK cells and cytotoxic T cells but also in monocytes and granulocytes [16]. Monoclonal antibody-mediated crosslinking had been used to activate the receptor and study functional aspects. In NK cells, such CD300a crosslinking resulted in an inhibition of cytotoxic activity via tyrosin phosphorylation of ITIM motifs and a subsequent recruitment of SHP-1 and SHP-2 phosphatases [16]. In mast cells, CD300a engagement inhibited IgE-dependent mast cell activity and SCF mediated survival by recruiting SHP-1 and SHP-17. An inhibitory role of CD300a was also observed in eosinophils where antibody-engagement of the receptor suppressed the effect of eotaxin, IL-5, and GM-CSF by recruiting the SHP-1 phosphatase [18]. Furthermore, CD300a can modulate the function of someactivating receptors such as CD32a in neutrophils [19] and kit in mast cells [20]. Here, we show that an inhibitory role of CD300a also extends to monocyte transendothelial migration since this process is inhibited by antibody-engagement of the receptor. Thus, upregulation of CD300a during transendothelial migration appears to represent a means of fine-tuning monocyte activity and counteracting the migratory stimulation possibly following the actual transendothelial passage.

**Materials and Methods**

**Cell culture and primary cell isolation, DNA constructs and siRNAs**

HMEC-1 cells were cultivated at 37°C and 3% CO2 in MCDB-151 medium supplemented with 10% FCS Gold, 20 mM L-glutamine, 50 µg/ml gentamycin, 10 ng/ml epidermal growth factor and 10 µg/ml hydrocortisone.

Human peripheral blood monocytes were isolated from buffy coats [21]. In brief, density centrifugation was performed using the Ficoll separation solution with a density of 1,177 g/ml (PAA Laboratories, Germany) to isolated mononuclear cells. In a second round of centrifugation, monocytes were enriched using Percoll separation solution with a density of 1,139 g/ml (Amersham Biosciences, Germany). After washing, the cells were cultured overnight in McCoy's 5A medium supplemented with 15% FCS, penicillin/streptomycin and 2 mM L-Glutamine in Teflon-coated bags to prevent adherence and subsequent activation. Monocyte purity was routinely >80% when assessed by counting in a Coulter Counter Z2 (Coulter, Krefeld, Germany).

For ectopic expression full length cDNA encoding CD300a (maGenes) was cloned into pcDNA3.1 (-) (Invitrogen) and pEGFP-N3 (Clontech) expression vectors. CD300a knock-down experiments employed freshly isolated monocytes (2 x 10⁷/100 µl) that were transfected with specific Stealth siRNA oligonucleotides directed at CD300a (5'-UCA CUG CGG CCA AGA CCA UAA-3') or control siRNAs (Invitrogen) using the Amaxa transfection method (Lonza, Germany). Transmigration was assessed two days after transfection using the assay described below.

**Transmigration assay**

HMEC-1 cell monolayers were employed in monocyte transmigration analyses as described previously [22]. Briefly, 2.2 x 10⁶ HMEC-1 cells were seeded on fibronectin-coated transwell filters with a 3 µm pore size (Corning) and grown to confluency. After 48 hours, medium and non-adherent cells were removed and 600 µl assay medium (DMEM with 4.5 g/l glucose supplemented with 10% FCS Gold and 20 mM L-glutamine) were added to the lower compartment of a two chamber system separated by the transwell filters. 2 x 10⁶ monocytes in 100 µl assay medium were added to the upper chamber, and cells were subsequently incubated at 37°C and 5% CO2 for 4 hours. Cells that had transmigrated through the endothelial monolayer were recovered in the lower culture chamber and counted in a Z2 Coulter Counter. To verify the integrity of the endothelial monolayer after the assay, the upper chamber was washed twice with phosphate-buffered saline (PBS), stained with DiffQuick (Dade Behring, Dudingen, Switzerland), air-dried, and mounted on glass slides for microscopic analysis. CD300a antibody-engagement experiments were carried out by incubation of freshly isolated monocytes (2 x 10⁶/100 µl) with 15 µg/ml of the anti-CD300a E59.126 [16] or matched control antibodies (anti-c-myc, Exalpa Biologicals; and anti-p58.2, Abcam) at 37°C, 5% CO2 for 30 minutes. Afterwards cells were subjected to the migration assay.

**DNA microarray analysis**

Microarray hybridization was carried out with monocyte mRNA from three independent transmigration experiments. In each experiment, transmigrated monocytes were compared to monocytes from the same preparation kept for the same time under identical conditions in tissue culture dishes in the absence of endothelial cells. Total cellular RNA was then isolated from migrated and control monocytes using the RNeasy kit (Qiagen, Hilden, Germany). RNA was quantified by UV spectrophotometry and integrity was verified by agarose gel electrophoresis. Samples for microarray hybridisation were prepared according to the manufacturer’s instructions and 10 µg of fragmented cRNA were hybridised to Affymetrix Human Genome U95Av2 Gene Chip arrays according to the manufacturer’s instructions (Affymetrix, Santa Clara, CA). Arrays were washed and stained using the Gene Chip Fluidics station 400 (Affymetrix). Fluorescence signals were recorded by the HP G2500A Gene Array Scanner (Affymetrix) and data were processed by MicroArray suite (MAS) software 5.0 (Affymetrix).

**Real-time quantitative PCR**

RNA was isolated from transmigrated monocytes or non-migrated monocytes as described above. Reverse transcription was performed using 6 µg of total RNA and 100 pmol/µl of a T7(βT) primer (5’-GCCAGTGAATTTGTAATACGACTCACTATAGGGAGCCGGTTTTTTTTTTTTTTTTTTTTTTTTTTTT-3’). The cDNA was subjected to real-time PCR using an ABI prism 7900 HT RT-PCR system. Primer sequences used for the amplification of the genes selected are given in Table 1. Expression level of all genes were normalized to GAPDH controls amplified with oligonucleotides 5’-CTTGCATTGAGCTCACTAGT-3’ (sense) and 5’-TGTTGATTTCCCTTGCCGACC-3’ (antisense) using the 2-C(t) -ΔC(t)-method [23].

**Transfection and immunostaining of COS-7 cells**

COS-7 cells were transfected with the full length CD300a construct using Effectene (Qiagen). Two days after transfection, cells were treated with 5 µg/ml anti-CD300a antibodies and incubated for 20 minutes. In some experiments, 4 µM cytochalasin D (Calbiochem) were added to the cells for 30 minutes to disrupt the actin cytoskeleton. Cells were then fixed with 4% formaldehyde, permeabilized with 0.5% Triton X-100 and treated with 3% BSA in PBS for 1 h at room temperature. Staining employed Alexa-Fluor 488 anti-mouse antibodies (Dianova) to detect surface-associated anti-CD300a antibodies and Phalloidin-TRITC (Sigma) to label F-actin. Immunostained cells were
analysed with a LSM 510 META Laser Scanning Microscope (Zeiss).

**Actin-sedimentation assay**

COS-7 cells ectopically expressing full length CD300a were lysed in 0.5% Triton X-100, 10 mM Tris/HCl, pH 7.4, 1 mM MgCl₂ with protease inhibitors and centrifuged at 40,000 g for 30 minutes. Supernatants were collected into new tubes, treated with 10 μM nocodazole (Sigma) to disrupt microtubules and subjected to ultracentrifugation (50,000 g, 5 minutes) to pellet actin filaments. Pellets were resuspended in SDS-sample buffer and, together with samples of the total lysates, were subjected to immunoblot analysis using anti-CD300a (E59.126) and anti-actin antibodies.

**Immunofluorescence of monocytes**

Freshly isolated monocytes were pre-incubated with anti-CD300a antibodies (E59.126, 5–15 μg/ml) or isotype matched control antibodies (anti-cmyc; Exalpa Biologicals, 5–15 μg/ml) for 10 minutes at 37°C, 5% CO₂. Thereafter, the cells were seeded on coverslips and incubated for another 30 minutes, fixed with methanol (−20°C) and stained with anti-CD300a antibodies followed by Alexa-Fluor 488 anti-mouse antibodies (Dianova) and Phalloidin-TRITC. Immunostained cells were analysed with a LSM 510 META Laser Scanning Microscope.

**Adhesion assay**

Monocytes (1×10⁵) were treated with LPS (5 μg/ml), anti-LFA-1 (20 μg/ml, Thermo scientific), anti-c-myc or anti-CD300a antibodies (5 μg/ml each) and then added to confluent HMEC-1 followed by incubation at 37°C. Non-adherent cells were removed by washing with PBS containing Ca²⁺/Mg²⁺ and the amount of adherent cells was determined by measuring myeloperoxidase activity [22]. In order to exclude an effect of anti-CD300a antibodies on monocytes adhesion, integrin activation following antibody treatment was analysed using a monoclo-

---

**Table 1. Primers used for real time RT-PCR.**

| Accession | Gene symbol | Description | Primer sequence (5’–3’) |
|-----------|-------------|-------------|------------------------|
| AI687419  | AI687419    | AI687419    | GGAGAATTGGAAACGAATGGA [s] |
| U83171    | CCL22       | chemokine (C-C motif) ligand 22 | GCCGTGGTGGCTCACTTCTGCTTCA [a] |
| AF20314   | CD300A      | CD300A antigen | CTTTGTAATCCAGCCCGCATGATG [s] |
| L31584    | CCR7        | chemokine (C-C motif) receptor 7 | GATGAGAGTCGGCGAAGATTACAT [s] |
| U03057    | FSCN1       | fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus) | AGCAAGATGGCAAGCTGCTTCA [a] |
| M60974    | GADD45A     | growth arrest and DNA-damage-inducible, alpha | AAGCCGGAAAGGATGGATAAGGT [s] |
| U82278    | LILRA2      | leukocyte immunoglobulin-like receptor, subfamily A, member 2 | ATACAGAAGCTGGAGAAGAATGG [s] |
| Z14138    | MAP3K8      | mitogen-activated protein kinase kinase kinase 8 | GCCGCCGCCTGGCTACA [a] |
| X55740    | NTSE        | 5′-nucleotidase, ecto (CD73) | CCGCTTCATGACGAGCTGCTTCA [a] |
| AB023209  | PALLD       | palladin | GCTTGGTGTGGCTGACTAAGAAG [s] |
| 567334    | PIK3CB      | phosphatidylinositol 3-kinase p110 beta isoform = 110 kda catalytic subunit | CTAATGTGTCAAGCTGGGATAAG [s] |
| AJ001014  | RAMP1       | receptor (calctinin) activity modifying protein 1 | GGAATAATCTTGGCCAGCTTGTGTA [a] |
| L13463    | RG52        | regulator of G-protein signalling 2, 24kDa | TGGGAGGCGCTTGGCTGAGTTAG [a] |
| AJ132099  | VNN1        | vanin 1 | TGAGTGTGGATGGGATGATG [s] |

**doi:10.1371/journal.pone.0073981.t001**
nal antibody (9EG7) that recognizes the activated form of the integrin β1 [24]. Monocytes were treated with MnCl₂ (5 mM; activation control), anti-c-myc or anti-CD300a antibodies (5 µg/ml each) for 30 minutes at 37°C. Thereafter, cells were incubated with 15% human serum (to block Fc receptors) in PBS supplemented with 0.1% bovine serum albumin for 10 minutes on ice. Anti-integrin β1 antibodies (9EG7, kindly provided by Prof. Lydia Sorokin) were added for 45 minutes at 4°C, followed by appropriate secondary antibodies and the signals were recorded using a FACS Calibur cytometer (BD Biosciences, Heidelberg, Germany).

Flow cytometry and internalization

For FACS analysis monocytes (1×10⁶) were incubated with 15% human serum (to block Fc receptors) in PBS supplemented with 0.1% bovine serum albumin for 30 minutes on ice. Thereafter, anti-CD300a or anti-p58.2 antibodies were added followed by appropriate secondary antibodies and the stainings were analysed using a FACS Calibur cytometer (BD Biosciences, Heidelberg, Germany). To analyse total CD300a expression, cells were permeabilized with cold 70% methanol for 10 minutes at 4°C, followed by blocking and staining as described above. For internalization assays, freshly isolated human monocytes were incubated for different periods of time with anti-CD300a antibodies either at 4°C or at 37°C. Cells were then stained with

Figure 1. CD300a is upregulated in transmigrated monocytes. Freshly prepared human monocytes were allowed to transmigrate across a monolayer of HMEC1 cells for 4 hours at 37°C, 5% CO₂. A. Mean fluorescence intensity of cell surface CD300a expression obtained by FACS analysis of anti-CD300a antibody stained cells revealing CD300a on the surface of monocytes before and after transendothelial migration. Data presented are from three independent experiments. Statistical significance was evaluated using student’s t-test and ratio paired t-test * P<0.05. B. Representative FACS analysis revealing total CD300a levels before and after transendothelial migration. Control cells were incubated without primary and secondary (control 1) or only with secondary antibodies (control 2).

doi:10.1371/journal.pone.0073981.g001
transendothelial migration belong to different functional categories. We therefore subjected the microarray data to further analysis in order to identify biological processes that were statistically overrepresented among these genes using the functional annotation clustering function of the “Database for Annotation, Visualization and Integrated Discovery” (DAVID) 2006 software [25,26]. Two of the 156 genes found to be up- or downregulated with an average expression change of at least 1.8-fold showed an average expression change of at least 1.8-fold with p values of less than 0.05 in three independent transmigration and microarray hybridization experiments. The expression changes observed ranged from 14.9-fold down-regulation (IL24) to 9.2-fold up-regulation (VLDLR). A comprehensive list of all genes exhibiting differential expression after adhesion to and migration through an endothelial monolayer is shown in Tables S1 and S2.

In order to confirm the regulations observed in the microarray analysis, we again carried out independent transmigration experiments and subjected 14 of the genes identified in the initial screens to validation by real-time RT-PCR. The genes were chosen to cover a variety of molecular functions, and we only considered the regulation as confirmed if the average regulation in three independent transmigration/RT-PCR experiments matched the direction of regulation observed in the microarray experiments. For 12 of the selected genes we could confirm the direction of regulation found in the microarray experiments (upregulated genes: CD300a, MAP3K8, NT5E, PIK3CB; downregulated genes: AI687419, CCL22, CCR7, FSCN1, GADD45A, RAMP1, RGS2, VNN1) (Table 2). Only the regulation of LILRA2 and PALLD could not be confirmed in the RT-PCR analysis, most likely due to very low absolute expression levels.

### Functional annotation clustering of differentially expressed genes

The genes differentially expressed following monocyte transendothelial migration belong to different functional categories. We therefore subjected the microarray data to further analysis in order to identify biological processes that were statistically overrepresented among these genes using the functional annotation clustering function of the “Database for Annotation, Visualization and Integrated Discovery” (DAVID) 2006 software [25,26]. Two of the 156 genes found to be up- or downregulated with an expression change of at least 1.8-fold lacked functional gene ontology (GO) annotation and thus could not be considered in the

### Table 2. Changes in gene expression of human monocytes induced after transendothelial migration analyzed by realtime RT-PCR.

| Accession | Gene symbol | Description | Avg. N-fold (microarray) | Avg. N-fold (RT-PCR) |
|-----------|-------------|-------------|--------------------------|----------------------|
| S67334    | PIKCB       | phosphatidylinositol 3-kinase p110 beta isoform = 110 kda catalytic subunit | 2.40 | 1.93 |
| AF020314  | CD300A      | CD300A antigen | 3.56 | 2.83 |
| X55740    | NT5E        | 5'-nucleotidase, ecto (CD73) | 2.05 | 1.85 |
| U82278    | LILRA2      | leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 2 | 1.83 | -1.05 |
| Z14138    | MAP3K8      | mitogen-activated protein kinase kinase kinase 8 | 1.83 | 1.6 |
| AB023209  | PALLD       | palladin | -2.48 | 1.03 |
| A1687419  | A1687419    | | -2.93 | -3.3 |
| M60974    | GADD45A     | growth arrest and DNA-damage-inducible, alpha | -2.89 | -3.83 |
| U03057    | FSCN1       | fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus) | -2.70 | -2.34 |
| U83171    | CCL22       | chemokine (C-C motif) ligand 22 | -2.89 | -3.16 |
| L31584    | CCR7        | chemokine (C-C motif) receptor 7 | -2.89 | -2.66 |
| L13463    | RGS2        | regulator of G-protein signalling 2, 24kDa | -3.17 | -4.4 |
| AJ132099  | VNN1        | vanin 1 | -2.70 | -2.3 |
| AJ001014  | RAMP1       | receptor (calcitonin) activity modifying protein 1 | -7.46 | -9.31 |

doi:10.1371/journal.pone.0073981.t002
Annotation clustering analysis. Using level 4 biological function gene ontology annotation for the remaining 154 genes, DAVID identified two clusters of GO branches containing genes that were statistically overrepresented in comparison to the Affymetrix HG-U95Av2 background gene list. The two clusters contained genes associated with inflammation/immune response ($p = 0.001$; Table 3) and metabolism ($p = 0.016$; Table 4), respectively. At least some of the latter are involved in pathways that lead to the production of inflammatory or anti-inflammatory mediators thus showing a relation to inflammatory processes as well.

**Antibody-mediated engagement and downregulation of CD300a affect monocyte transendothelial migration**

Our microarray data revealed a significant (about 3.5 fold) upregulation of the mRNA for the inhibitory immune receptor

---

**Figure 2. CD300a activation by antibody-engagement on the cell surface of monocytes results in a significant reduction of transendothelial migration.**

A. Cell surface expression of CD300a and p58.2 antigens on human monocytes was analysed by FACS using anti-CD300a and anti-p58.2 antibodies. Control cells were incubated without primary and secondary (control 1) or only with secondary antibodies (control 2). B. Freshly isolated human monocytes ($2 \times 10^6$) were incubated with mouse monoclonal anti-CD300a (E59.126) or control antibodies (anti-cmyc and anti-p58.2), respectively, and then subjected to transendothelial migration assays in a two-chamber set-up. Migrated cells were collected from the lower chamber and counted using a cell culture analyzer. The number of transmigrated cells is given on the y-axis. Three independent experiments were performed and results are presented as average +/- SEM. Statistical significance was evaluated using student’s t-test. * $P < 0.05$.
CD300a in migrated as compared to stationary monocytes. To determine whether the increased CD300a mRNA levels also result in elevated cell surface protein levels, we performed FACS analyses of monocytes before and after transendothelial migration employing monoclonal anti-CD300a antibodies. Figure 1A reveals that cell surface CD300a levels are also increased following the transendothelial migration of monocytes. Most likely, this increase is not due to translocation to the cell surface of an existing intracellular pool of the receptor, as the total level of CD300a shows a similar increase after transendothelial migration, indicative of new CD300a protein synthesis (Figure 1B). CD300a is a cell surface receptor of poorly characterized ligand profile and engagement of CD300a by specific antibodies has been shown to trigger receptor phosphorylation and activation in different haematopoetic cell types [16–18]. Therefore we employed this protocol to investigate a possible role of CD300a in monocyte transendothelial migration. Freshly isolated human monocytes were incubated with mouse anti-CD300a antibodies and allowed to transmigrate across the HMEC-1 monolayer. Control experiment employed isotype matched mouse IgGs and anti-p38.2 antibodies [18] that were chosen to include another cell surface binding antibody (Figure 2A). Figure 2B reveals that monocytes treated with the anti-CD300a antibody show significantly reduced transmigration as compared to untreated, control IgG-treated or anti-p58.2 treated cells. This effect on transmigration was not due to an altered adhesion capacity of the antibody-treated cells as revealed by quantification of HMEC-1 adherent monocytes in the presence of anti-CD300a versus control antibodies (Fig. 3A). Moreover, anti-CD300a antibody treatment did not affect β1 integrin activation in monocytes that was visualized by probing with an antibody recognizing an active integrin conformation (9EG7) (Fig. 3B).

To confirm a functional role of CD300a in regulating the transendothelial migration of monocytes, we used specific siRNA oligonucleotides to knock down CD300a expression. We first verified the efficiency of the siRNA treatment in COS-7 cells that were co-transfected with CD300a-GFP and non-targeting or CD300a-targeting siRNAs, respectively. Western blot analysis of cell lysates prepared 24 h post transfection revealed a significant downregulation of CD300a-GFP in cells transfected with the CD300a-specific siRNA (Figure S1). Next, the efficacy of siRNA-mediated CD300a downregulation was analyzed in monocytes transfected

| Table 3. Monocyte genes associated with inflammation and immune response found in DAVID functional annotation clustering of the genes differentially expressed following transendothelial migration. |
|---|
| **Inflammation/immune response related genes** |
| **Accession** | **Description** | **nfold** |
| X68487 | adenosine A2b receptor | 1.87 |
| D83597 | cd180 antigen | 4.09 |
| U47924 | cd4 antigen (p55) | 1.95 |
| M31516 | cd55 antigen, decay accelerating factor for complement (cromer blood group) | 1.95 |
| Z11697 | cd83 antigen (activated b lymphocytes, immunoglobulin superfamily) | 2.09 |
| U83171 | chemokine (c-c motif) ligand 22 | 2.89 |
| Y16645 | chemokine (c-c motif) ligand 8 | 2.19 |
| L31584 | chemokine (c-c motif) receptor 7 | 2.89 |
| AF054176 | chromosome 1 open reading frame 7 | 1.91 |
| J02931 | coagulation factor iii (thromboplastin, tissue factor) | 3.73 |
| L12691 | defensin, alpha 1 | 3.56 |
| X06948 | fc fragment of ige, high affinity i, receptor for; alpha polypeptide | 2.05 |
| K03515 | glucose phosphate isomerase | 2.00 |
| U10550 | gtp binding protein overexpressed in skeletal muscle | 9.19 |
| A160656 | immunoglobulin j polypeptide, linker protein for immunoglobulin alpha and mu polypeptides | 2.05 |
| M63438 | immunoglobulin kappa constant | 1.95 |
| M34551 | indoleamine-pyrrole 2,3 dioxygenase | 2.96 |
| L78833 | interferon-induced protein 35 | 2.14 |
| AB006537 | interleukin 1 receptor accessory protein | 3.32 |
| X52015 | interleukin 1 receptor antagonist | 2.19 |
| U14407 | interleukin 15 | 2.96 |
| U16261 | interleukin 24 | 14.93 |
| L19686 | macrophage migration inhibitory factor (glycosylation-inhibiting factor) | 3.10 |
| MB1750 | myeloid cell nuclear differentiation antigen | 2.14 |
| S77154 | nuclear receptor subfamily 4, group a, member 2 | 3.40 |
| U004636 | prostaglandin-endoperoxide synthase 2 (prostaglandin g/h synthase and cyclooxygenase) | 1.91 |
| J04765 | secreted phosphoprotein 1 (osteopontin, bone sialoprotein i, early t-lymphocyte activation 1) | 8.98 |
| AL031983 | ubiquitin d | 3.91 |

doi:10.1371/journal.pone.0073981.t003
Figure 3. Antibody-engagement of CD300a has no effect on monocyte-endothelial adhesion and integrin activation. A. Monocytes were treated with LPS, anti-LFA-1, anti-c-myc or anti-CD300a antibodies and then added to HMEC-1 cells grown in 96 well plates followed by incubation at 37°C. Non-adherent cells were removed by washing with PBS containing Ca++/Mg++ and the amount of adherent cells was determined by measuring the myeloperoxidase activity that is given as OD450 values on the y-axis. Three independent experiments were performed and results are presented as average +/- SEM. Statistical significance was evaluated using student’s t-test. ** P<0.01 and *** P<0.005. B. Monocytes were treated first with MnCl₂ (positive control), anti-c-myc (negative control) or anti-CD300a antibodies for 30 minutes at 37°C and then at 4°C for 45 minutes with 9EG7 antibodies recognizing the active conformation of β1 integrins. 9EG7 antibodies were then stained with appropriate secondary antibodies followed by FACS analysis.
doi:10.1371/journal.pone.0073981.g003
with either control or CD300a-specific siRNAs. Cell surface CD300a was detected by antibody staining two days after transfection revealing a considerable reduction in CD300a levels (Fig. 4A). Given this significant knockdown of surface CD300a, we subjected the CD300a-depleted monocytes to transendothelial migration 48 hours post transfection and compared the number of transmigrated cells to that of untransfected and control siRNA-transfected monocytes. While transfection with control siRNA led to a slight but statistically non-significant increase in transmigration, siRNA-mediated reduction of CD300a cell surface levels resulted in further increase in the number of transmigrated cells that was statistically significant (Fig. 4B).

### Association of CD300a with actin-rich surface structures

Monocyte transmigration requires coordinated alterations of cell shape that are mediated by actin cytoskeleton dynamics [27]. Therefore, towards understanding the mechanistic basis of CD300a action in monocyte transmigration we analyzed by subcellular localization studies whether CD300a could directly or indirectly associate with the actin cytoskeleton. Since details of cytoskeletal structures are difficult to visualize in peripheral blood monocytes, experiments were first carried out with COS-7 cells ectopically expressing CD300a. Staining with phalloidin and anti-CD300a antibodies revealed a partial colocalization of CD300a with F-actin, in particular along the cell surface and in actin-rich protrusions (Fig. 5A). It is noteworthy that CD300a localized to such structures but did not induce them, since they are also apparent in untransfected cells. Interestingly, localization of CD300a to actin-rich protrusions was increased following engagement of the receptor with anti-CD300a antibodies. On the other hand, treatment of the cells with cytochalasin D abolished the CD300a- and actin-rich protrusions (Fig. 5B). An interaction of CD300a with F-actin was also evident in actin co-sedimentation assays performed with lysates of cells ectopically expressing CD300a. Figure 5C reveals a significant co-pelleting of CD300a with actin filaments in extracts from transfected cells.

### Table 4. Monocyte genes associated with metabolism found in DAVID functional annotation clustering of the genes differentially expressed following transendothelial migration.

| Accession | Description | nfold |
|-----------|-------------|-------|
| D14874    | adrenomedullin | 2.19  |
| J05032    | aspartyl-tma synthetase | 2.14  |
| AL021546  | cytochrome c oxidase subunit via polypeptide 1 | 1.82  |
| AF002668  | degenerative spermatocyte homolog 1, lipid desaturase (drosophila) | 1.87  |
| M55914    | enolase 1, (alpha) | 1.91  |
| U21931    | fructose-1,6-bisphosphatase 1 | 2.09  |
| L07956    | glucan (1,4-alpha), branching enzyme 1 (glycogen branching enzyme, anderson disease) | 2.70  |
| Z12173    | glucosamine (n-acetyl)-6-sulfatase (sanfilippo disease iiid) | -1.91 |
| K03515    | glucose phosphate isomerase | 2.00  |
| D16583    | histidine decarboxylase | -1.95 |
| D84424    | hyaluronan synthase 1 | -2.89 |
| M34455    | indoleamine-pyrole 2,3 dioxygenase | -2.96 |
| X76488    | lipoic acid, lysosomal acid, cholesterol esterase (wolman disease) | 1.87  |
| L19686    | macrophage migration inhibitory factor (glycosylation-inhibiting factor) | 3.10  |
| L22524    | matrix metallopeptidase 7 (matrilysin, uterine) | -5.79 |
| D25328    | phosphofructokinase, platelet | 3.32  |
| M83088    | phosphoglucomutase 1 | 2.52  |
| S81916    | phosphoglycerate kinase 1 | 2.89  |
| J04173    | phosphoglycerate mutase 1 (brain) | 1.91  |
| L42450    | pyruvate dehydrogenase kinase, isozyme 1 | 2.64  |
| L42452    | pyruvate dehydrogenase kinase, isozyme 3 | 3.17  |
| J05037    | serine dehydratase | -3.32 |
| M20681    | solute carrier family 2 (facilitated glucose transporter), member 3 | 2.30  |
| D78130    | squalene epoxidase | 2.00  |
| U47924    | triosephosphate isomerase 1 | 1.95  |
| X90858    | uridine phosphorylase 1 | 1.95  |
| D16532    | very low density lipoprotein receptor | 9.19  |

DOI:10.1371/journal.pone.0073981.t004
Figure 4. siRNA-mediated downregulation of CD300a increases monocyte transendothelial migration. 

A. FACS analysis of cell surface CD300a expression in monocytes transfected with control or CD300a siRNAs, respectively, employing mouse monoclonal anti-CD300a and appropriately labelled secondary antibodies. Control cells were incubated without primary and secondary (control 1) or only with secondary antibodies (control 2). 

B. Freshly isolated monocytes from human buffy coats were transfected with control or CD300a siRNAs, respectively, followed by transendothelial migration analysis. The number of transmigrated cells is given on the y-axis. Three independent experiments were performed and results are presented as average +/- SEM. Statistical significance was evaluated using student’s t-test. * P<0.05.

doi:10.1371/journal.pone.0073981.g004
Figure 5. CD300a associates with F-actin in COS-7 cells. A. COS-7 cells were transfected with a CD300a expression construct and the subcellular localization of CD300a was then revealed by staining with anti-CD300a antibodies. TRITC-phalloidin was used to label the actin cytoskeleton. The bottom row of images shows cells treated with cytochalasin D (4 μM) to disrupt actin filaments. B. COS-7 cells ectopically expressing CD300a were incubated with monoclonal anti-CD300a antibodies to activate cell surface receptors. Cells were then left untreated or treated with 4 μM cytochalasin D followed by fixation and staining with anti-CD300a antibodies and TRITC-phalloidin. Note the localization of CD300a in Monocyte Transendothelial Migration.
CD300a to actin-rich cell protrusions that is increased following the anti-CD300a antibody treatment (arrowhead). Scale bars, 10 μm. 

C. Coprecipitation of CD300a with actin filaments. Triton lysates of control (non-transfected) or CD300a expressing COS-7 cells (transfected) were treated with nocodazole to depolymerize microtubules and then subjected to high speed centrifugation to pellet actin filaments. CD300a protein was detected in the actin pellet fraction suggesting a direct or an indirect association of the protein with F-actin. Input shows protein levels in the cell lysates prior to high speed centrifugation. doi:10.1371/journal.pone.0073981.g005

with extended lamellipodia. Isotype-matched control IgGs failed to elicit these morphological changes (Fig. 6).

Discussion

Transendothelial migration is known to lead to changes in leukocyte biology which enable the cells to function efficiently when reaching the underlying tissue [11]. In line with this, our functional annotation clustering analysis of genes differentially expressed in transmigrated monocytes revealed the highest enrichment score for genes associated with inflammation/immune response. Some of the differentially regulated genes have well-known functions in monocyte-mediated immune responses, such as the interleukin 1 receptor antagonist (IL1RN) [28]. Others, however, are known to play a role in inflammation in general, but have not yet been characterized in monocytes. One such example is CD300a, which is an inhibitory receptor in human NK cells [16] and eosinophils [18] but is also expressed in other leukocytes and was chosen here for further analysis with respect to its potential role in monocyte transmigration.

Our microarray analysis also identified several transcription factors and proteins that modulate transcription factor activity among the differentially expressed genes. These include members of the NR4A nuclear hormone receptor subfamily, NR4A2 and NR4A3, which are known to modulate inflammatory responses [29], and the human myeloid nuclear differentiation antigen (MNDA) [30]. The latter had been implicated in myeloid cell differentiation, although its functional role in this process is unclear [31]. In line with such role of MNDA we obtained additional evidence that transendothelial migration triggered early steps of monocyte differentiation. Comparison of the transcription profile of transmigrated monocytes with that observed upon monocyte-to-macrophage differentiation in phorbol 12-myristate 13-acetate (PMA)-treated U937 cells or cytokine-treated human peripheral blood monocytes [32,33] revealed that the regulation of several genes, e.g. CCR7, DEFA1, IL1RN, IL15, INDO and SPP1, is common in both scenarios. Thus, altogether our profiling
Inhibitory receptors such as CD300a play critical roles in the regulation of different immune cell functions. Loss of inhibitory signalling is often associated with auto-reactivity and excessive inflammatory responses indicating the important role of such inhibitory systems and identifying them as potential targets for the treatment of immune disorders [20,34]. We show here that CD300a is upregulated during monocyte transendothelial migration not only at the RNA but also at the cell surface protein level. How does this translate to a potential function in monocyte extravasation? In line with an inhibitory role of CD300a, its engagement by specific antibodies inhibits the transendothelial migration of monocytes. This inhibitory effect is similar to that elicited by anti-CD300a antibody engagement on the migration of eosinophils in response to eotaxin [18]. Antibody engagement could induce receptor endocytosis and thereby reduce cell surface levels of CD300a that normally might be required for efficient transmigration. Indeed, the mouse homologue of CD300a (MAIR1/CML-8) contains a YVNL sequence in its cytoplasmic part that is involved in internalization [35] and an internalization motif is also found in the cytoplasmic domain of human CD300a [36]. Therefore, we analysed a possible CD300a internalization following receptor engagement. However, FACS analysis showed no difference in surface expression of CD300a before and after antibody engagement (Figure S2). Thus, we exclude a possible reduction of cell surface CD300a levels in response to antibody treatment in our experiments.

In order to pass through the vessel wall, monocytes need to change their shape, a process accompanied by major cytoskeletal rearrangements [27]. Correlations between inhibitory receptors and actin cytoskeleton dynamics have been reported but are not yet known for CD300a [37–39]. Our study reveals for the first time such a relation between CD300a and the actin cytoskeleton. CD300a localizes to actin-rich protrusions that are also positive for ezrin (Figure S3), a protein known to connect membrane receptors to the actin cytoskeleton (for review see [40]). Hence, ezrin might serve as a linker between cell surface CD300a and underlying cortical actin, thereby physically translating CD300a engagement to changes in the actin cytoskeleton. Other, more indirect links between CD300a and the regulation of actin dynamics can also be envisaged. Engagement of CD300a results in phosphorylation of its ITIMs and the recruitment of SHP phosphatases [18]. This could affect actin dynamic because it has been shown that actin is a direct SHP-1 substrate in B cells [41]. BCR crosslinking using specific mAbs results in SHP-1 recruitment and subsequent actin dephosphorylation and F-actin depolymerization. Moreover, Vav1, which is an important regulator of actin dynamics, is also a direct substrate of SHP-1 [42], and its dephosphorylation could represent an important event downstream of CD300a engagement. Alternatively, a physical connection between CD300a and cortical actin might be necessary for the proper recruitment of phosphatases to activated CD300a, similar to what has been observed for FCγRIIB in mast cells [43]. Here, the interaction of FCγRIIB with actin has been shown to be required for enhancing the negative regulatory effect of this receptor towards FcγRI [43]. The role of actin in this case has been assumed to be that of a scaffold protein stabilizing the SHP-1-FCγRIIB interaction.

As all these receptor-actin interactions appear to negatively regulate cell activities, it is not surprising that antibody engage-

Supporting Information

Figure S1 Efficient Knockdown of CD300a expression. To analyse the efficiency of CD300a downregulation, COS-7 cells were co-transfected with CD300a-GFP and control or CD300a siRNA duplexes, respectively. Expression of CD300a-GFP was then analysed by immunoblotting of cell lysates using anti-CD300a antibodies. The amount of actin in the cell lysates is shown as a loading control. (TIF)

Figure S2 Antibody engagement of cell surface CD300a does not result in receptor internalization. Freshly isolated human monocytes were incubated for different periods of time with anti-CD300a antibodies or phalloidin-TRITC. CD300a localizes to ezrin positive protrusions (arrowhead) which also contain actin. (TIF)

Figure S3 Localization of CD300a in ezrin positive protrusions. Cos-7 cells were transfected with the pcDNA-CD300a construct and stained with rabbit anti-ezrin and mouse anti-CD300a antibodies or phalloidin-TRITC. CD300a localizes to ezrin positive protrusions (arrowhead) which also contain actin. (TIF)

Table S1 List of monocyte genes upregulated following transendothelial migration. (DOC)

Table S2 List of monocyte genes downregulated following transendothelial migration. (DOC)

Acknowledgments

We thank Anuaka Eijen for help with the COS-7 cell experiments.

Author Contributions

Conceived and designed the experiments: SG CL VG. Performed the experiments: SG CL. Analyzed the data: SG CL. CB VG. Contributed reagents/materials/analysis tools: SG CL. CB VG. Wrote the paper: SG CL. VG.
1. Choi EY, Santoso S, Chavakis T (2009) Mechanisms of neutrophil transendothelial migration. Front Biosci 14: 1596–1605.
2. Ley K, Laudanna C, Gybicky M, Nourshargh S (2005) Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 7: 678–689.
3. Muller WA (2011) Mechanisms of Leukocyte Transendothelial Migration. Annual Review of Pathology: Mechanisms of Disease 6: 323–344.
4. van Buul JD, Horák P (2004) Signaling in Leukocyte Transendothelial Migration. Arteriosclerosis, Thrombosis, and Vascular Biology 24: 824–833.
5. Woodfin A, Voisin M-B, Nourshargh S (2010) Recent developments and complexities in neutrophil transmigration. Current Opinion in Hematology 17: 10–17.
6. Imhof BA, Arrand-Lions M (2004) Adhesion mechanisms regulating the migration of monocytes. Nat Rev Immunol 4: 432–444.
7. Zarbock A, Ley K, McEver RP, Hidalgo A (2011) Leukocyte ligands for extracellular signals: specialized glycosphingolipids that mediate rolling and signaling under flow. Blood 118: 6734–6751.
8. de Fougerolles AR, Chi-Russo G, Bajardi A, Gotval P, Green CD, et al. (2000) Global Expression Analysis of Extracellular Matrix-Integrin Interactions in NK cells. European Journal of Immunology 29: 3148–3159.
9. Rossetti G, Collinge M, Mohreni R, Bender JR, Pardi R (2002) Integrin-dependent regulation of gene expression in leukocytes. Immunological Reviews 186: 189–207.
10. Shi C, Simon DI (2006) Integrin Signals, Transcription Factors, and Monocyte Migration. Journal of Immunology 175: 1084–1089.
11. Livak KJ, Schmittgen TD (2001) Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2-ΔΔ Ct Method. Methods 25: 402–408.
12. Lenter M, Uhlig H, Hamann A, Jeno P, Imhof B, et al. (1993) A monoclonal antibody against an activation epitope on mouse integrin αβ1 blocks adhesion of lymphocytes to the endothelial integrin α6β1. Proceedings of the National Academy of Sciences 90: 9051–9053.
13. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3.
14. Hosack DA, DGEI, Sherman BT, Lane HC, Lempicki RA (2003) Identifying biological themes within lists of genes with EASE. Genome Biol 4: R70.
15. Weber KSC, Klickstein LB, Weber PC, Weber C (1998) Chemokine-induced monocyte transmigration requires cdc42-mediated cytoskeletal changes. European Journal of Immunology 28: 2245–2255.
16. Arend WP, Malaya K, Gehrtridge CJ, Gabay C (1998) Interleukin-1 receptor antagonist: Role in Biology. Annual Review of Immunology 16: 27–55.
17. Botta PL, van Tiel CM, Voss M, Poli TWH, van Thienen JV, et al. (2006) Nuclear Receptors Nur77, Nur1, and NOR-1 Expressed in Atherosclerotic Lesion Macrophages Reduce Lipid Loading and Inflammatory Responses. Arteriosclerosis, Thrombosis, and Vascular Biology 26: 2208.
18. Briggs RG, Atkinson JB, Mirandu RN (2003) Variable expression of human myeloid specific nuclear antigen MNDA in monocyte lineage cells in atherosclerosis. Journal of Cellular Biochemistry 95: 293–301.
19. Asea B, Klarmann KD, Copeland NG, Gilbert DJ, Jenkins NA, et al. (2004) The interferon-inducible p200 family of proteins: a perspective on their roles in cell cycle regulation and differentiation. Blood Cells, Molecules, and Diseases 32: 155–167.
20. Martinez FO, Gordon S, Locati M, Mantovani A (2006) Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression. The Journal of Immunology 177: 7305–7311.
21. Verhoeckx KCM, Bijlma S, de Groene EM, Winkamp RF, van de Greiff J, et al. (2004) A combination of proteomics, principal component analysis and transcriptomics is a powerful tool for the identification of biomarkers for macrophage maturation in the U937 cell line. Proteomics 4: 1014–1028.
22. Tam SW, Deminsie S, Thomas D, Daeron M (2004) A bispecific antibody against human IgE and human FcεRI that inhibits antigen-induced histamine release by human mast cells and basophils. Allergy 59: 772–780.
23. Yotsumoto K, Okoshi Y, Shihuya K, Yamazaki S, Tahara-Hanada S, et al. (2005) Paired activating and inhibitory immunoglobulin-like receptors, MAIR-I and MAIR-II, regulate mast cell and macrophage activation. J Exp Med 198: 223–233.
24. Clark GJ, Ju X, Tate C, Hart DJN (2009) The CD300 family of molecules are evolutionarily significant regulators of leukocyte functions. Trends in Immunology 30: 209–217.
25. Kravetski R, Chen X, Orange JS, Strominger JL (2006) Formation of a WIP-, WASp-, actin-, and myosin II-containing multi-protein complex in activated NK cells and its alteration by KIR inhibitory signaling. The Journal of Cell Biology 175: 121–132.
26. Masilamani M, Nguyen C, Kabat J, Borrego F, Coligan JE (2006) CD94/NKG2A Inhibits NK Cell Activation by Disrupting the Actin Network at the Immunological Synapse. The Journal of Immunology 177: 5590–5596.
27. Toyama-Sorimachi N, Toyajima Y, Maruya M, Oueda A, Kobata T, et al. (2004) Ly49Q, a member of the Ly49 family that is selectively expressed on myeloid lineage cells and involved in regulation of cytoskeletal architecture. Proceedings of the National Academy of Sciences of the United States of America 101: 1016–1021.
28. Felton RG, McClatchey A, Bretscher A (2010) Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol 11: 276–287.
29. Baba T, Fusaki N, Maruya N, Iwamatsu A, Hozumi N (2003) Actin Tyrosine Phosphatase Is Essential for Actin Depolymerization After Membrane IgM Dephosphorylation by the Src Homology 1-Containing Protein Tyrosine Phosphatase. Journal of Immunology 171: 1503.
30. Lesouer B, Frimmel WH, Daeron M (2005) Dynamic Interactions of the Gamma Receptor IIb with Fibrinogen-Bound SHP1: Amplify Filamentosus Actin-Dependent Negative Regulation of Fc epsilon Receptor I Signaling. The Journal of Immunology 174: 1565–1573.
31. Nakahashi-Oda C, Tahara-Hanaoka S, Shoji M, Okoshi Y, Nakano-Yokomizo T, et al. (2012) Apoptotic cells suppress mast cell inflammatory responses via the CD300a in Monocyte Transendothelial Migration CD300a in Monocyte Transendothelial Migration.